drugset / Trial / NCT00233662

Safety and Tolerability of Repeat Courses of IM Alefacept

NCT00233662

Phase 3 Completed 400 enrolled Biogen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether repeat courses of alefacept, administered intramuscularly, are safe when given to chronic plaque psoriasis patients who are receiving standard dermatology treatments.

Timeline

Start
2002-12-01
Primary completion
Completion
2005-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Alefacept Protein / enzyme biologic

Indications